Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Apple Inc. (AAPL), QUALCOMM, Inc. (QCOM): Disruptions Needed

Page 1 of 2

Take the $2.8 trillion spent last year in the U.S. on health care and add another 70% to the total. The resulting amount, nearly $4.8 trillion, is what the federal government says we will spend by 2021.

However, there are some technologies available now or in the near future that could reduce those expenditures. Here are three disruptive health care technologies that show promise in slashing health-care costs over time.

1. Genetic diagnostic testing
Overdiagnosis gets little attention, but it could add significantly to the nation’s health-care costs. The term refers to scenarios where patients are diagnosed and treated for a disease that won’t result in serious health issues.

For example, more than 240,000 men in the U.S. are diagnosed with prostate cancer annually. Half of these patients are classified as low risk, with only a 3% likelihood of the cancer progressing. However, 90% of low-risk patients receive treatments such as radical prostatectomy or radiation. These procedures increase costs and can result in further complications including incontinence and impotence.

Genetic diagnostic testing has the potential to help prevent much of this unnecessary spending. Genomics Health is one of a handful of companies already developing these types of tests. The company markets genetic tests for breast, colon, and prostate cancer.  It also has other products in development to screen for lung cancer, melanoma, and renal cancer.

As one example of possible savings, consider Genomics Health’s prostate cancer test — which sells for slightly more tha $3,800. That’s much less expensive than the tens of thousands of dollars for the treatment procedures for the disease.

2. Point of care decision support
Almost 14 years ago, the Institute of Medicine estimated that medical errors in the U.S. could cost $29 billion annually and result in as many as 98,000 deaths each year. Since then, additional studies have come up with varying numbers, but all agree on the enormous cost in lives and dollars resulting from medical errors.

Clinical decision support — technology that helps physicians and other clinical professionals make better decisions — has often been mentioned as a possible solution for reducing medical errors. However, despite increased availability of clinical decision support systems, a 2012 study conducted by Duke University found that use of these systems isn’t widespread.

One reason behind the lack of high adoption rates could be that physicians haven’t historically been able to access systems at the point of care — where decisions are often made. However, that should change.

A survey last year by Vitera Healthcare found that 60% of health-care professionals own Apple Inc. (NASDAQ:AAPL) iPhones, with 45% using iPads. Around nine in 10 physicians expressed interest in using their mobile devices for reviewing and updating patient charts and ordering prescriptions — ideal applications for clinical decision support.
Apple Inc. (AAPL)Apple Inc. (NASDAQ:AAPL) has fostered a large ecosystem that now includes thousands of health-care applications, some of which already incorporate aspects of clinical decision support. In many ways, the company has revolutionized health care with its mobile devices.

Credit: Apple Inc. (NASDAQ:AAPL)

Another potential factor that could partially explain lower adoption of clinical decision support is the quality of the support that the technology has provided in the past. International Business Machines Corp. (NYSE:IBM) is one company intent on disruption for that front.

Big Blue is now applying its Watson technology that became champion on the television game show Jeopardy! to the world of health care. Watson will use its natural language capabilities, hypothesis generation, and evidence-based learning to sift through patients’ medical information and enormous volumes of clinical information available from clinical studies and journal articles to help physicians more accurately diagnose and recommend treatments.

Page 1 of 2
Loading Comments...